Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYNCAR-100 in CD19-Positive R/R B-ALL
NCT07429461Phase 1Recruiting
- Sponsor
- Zhejiang University
- Start
- Feb 2026
- Primary completion
- Dec 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SYNCAR-100 in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Zhejiang University. Primary endpoint: Adverse Events at 48 weeks. Started Feb 2026; status: recruiting.
02
Drugs
SYNCAR-100
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT07429461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07429461.